<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03735992</url>
  </required_header>
  <id_info>
    <org_study_id>RBK02-17-00424</org_study_id>
    <nct_id>NCT03735992</nct_id>
  </id_info>
  <brief_title>Mind-body Medicine for Patients With Malignant Hematological Diseases</brief_title>
  <official_title>Mind-body Medicine as a Supportive Strategy for Patients With Malignant Hematological Diseases: a Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universität Duisburg-Essen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Robert Bosch Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Universität Duisburg-Essen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized controlled trial aims to investigate the effectiveness of a mind-body group
      program as a supprtivemanagement strategy for fatigue in patients with malignant
      hematological diseases.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 6, 2017</start_date>
  <completion_date type="Anticipated">March 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>General Fatigue</measure>
    <time_frame>week 12</time_frame>
    <description>Multidimensional Fatigue Inventory (MFI) - General Fatigue Subscale</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>General Fatigue</measure>
    <time_frame>week 24</time_frame>
    <description>Multidimensional Fatigue Inventory (MFI) - General Fatigue Subscale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical Fatigue</measure>
    <time_frame>week 12</time_frame>
    <description>Multidimensional Fatigue Inventory (MFI) - Physical Fatigue Subscale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical Fatigue</measure>
    <time_frame>week 24</time_frame>
    <description>Multidimensional Fatigue Inventory (MFI) - Physical Fatigue Subscale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduced Activity</measure>
    <time_frame>week 12</time_frame>
    <description>Multidimensional Fatigue Inventory (MFI) - Reduced Activity Subscale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduced Activity</measure>
    <time_frame>week 24</time_frame>
    <description>Multidimensional Fatigue Inventory (MFI) - Reduced Activity Subscale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduced Motivation</measure>
    <time_frame>week 12</time_frame>
    <description>Multidimensional Fatigue Inventory (MFI) - Reduced Motivation Subscale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduced Motivation</measure>
    <time_frame>week 24</time_frame>
    <description>Multidimensional Fatigue Inventory (MFI) - Reduced Motivation Subscale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mental Fatigue</measure>
    <time_frame>week 12</time_frame>
    <description>Multidimensional Fatigue Inventory (MFI) - Mental Fatigue Subscale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mental Fatigue</measure>
    <time_frame>week 24</time_frame>
    <description>Multidimensional Fatigue Inventory (MFI) - Mental Fatigue Subscale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Qaulity of life</measure>
    <time_frame>week 12</time_frame>
    <description>Functional Assessment of Cancer Therapy - General (FACT-G)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Qaulity of life</measure>
    <time_frame>week 24</time_frame>
    <description>Functional Assessment of Cancer Therapy - General (FACT-G)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Depression</measure>
    <time_frame>week 12</time_frame>
    <description>Hospital Anxiety and Depression Scale - Depression subscale (HADS-D)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Depression</measure>
    <time_frame>week 24</time_frame>
    <description>Hospital Anxiety and Depression Scale - Depression subscale (HADS-D)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anxiety</measure>
    <time_frame>week 12</time_frame>
    <description>Hospital Anxiety and Depression Scale - Anxiety Subscale (HADS-A)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anxiety</measure>
    <time_frame>week 24</time_frame>
    <description>Hospital Anxiety and Depression Scale - Anxiety Subscale (HADS-A)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stress</measure>
    <time_frame>week 12</time_frame>
    <description>Perceived Stress Scale (PSS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stress</measure>
    <time_frame>week 24</time_frame>
    <description>Perceived Stress Scale (PSS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sleep</measure>
    <time_frame>week 12</time_frame>
    <description>Pittsburgh Sleep Quality Index (PSQI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sleep</measure>
    <time_frame>week 24</time_frame>
    <description>Pittsburgh Sleep Quality Index (PSQI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical activity</measure>
    <time_frame>week 12</time_frame>
    <description>Motion sensor (activPAL3, Pal Technologies, Glasgow, Schottland)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical activity</measure>
    <time_frame>week 24</time_frame>
    <description>Motion sensor (activPAL3, Pal Technologies, Glasgow, Schottland)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fatigability</measure>
    <time_frame>week 12</time_frame>
    <description>30-Second Chair Stand Test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fatigability</measure>
    <time_frame>week 24</time_frame>
    <description>30-Second Chair Stand Test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>week 12</time_frame>
    <description>Number of patients with adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>week 24</time_frame>
    <description>Number of patients with adverse events</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Treatment Expectation</measure>
    <time_frame>week 0</time_frame>
    <description>Visual Analogue Scale (VAS)</description>
  </other_outcome>
  <other_outcome>
    <measure>Treatment Satisfaction</measure>
    <time_frame>week 12</time_frame>
    <description>Client Satisfaction Questionnaire (CSQ)</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">94</enrollment>
  <condition>Hematologic Neoplasms</condition>
  <arm_group>
    <arm_group_label>Mind-body medicine group program</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients recieve an 11-week mind-body medicine group program including elements of mindfullness based stress reduction (MBSR), yoga, and education + treatment as usual.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Wait list</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Treatment as usual.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Mind-body medicine group program</intervention_name>
    <description>The group program is mainly based on MBSR. It further integrates elements of the mind-body medicine cancer program of the Benson-Henry Mind/Body Medical Institute at Harvard Medical School which is rooted in psychoneuroendocrinology and focuses on relaxation techniques, exercise, cognitive restructuring, diet, and social support. In addition, naturopathic methods of selfregulation and self-care are incorporated.</description>
    <arm_group_label>Mind-body medicine group program</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with malignant hematological diseases in complete remission after primary
             chemotherapy and/or radiation

          -  Physical and mental ability to attent 8 of 11 group units

        Exclusion Criteria:

          -  Chemotherapy, radiation, or rehabilitation programm during the study period

          -  Pregnancy

          -  Participation in other studies with behavioral interventions during the study period
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gustav Dobos, Prof. MD</last_name>
    <role>Study Director</role>
    <affiliation>Department of Internal and Integrative Medicine | Kliniken Essen-Mitte | Faculty of Medicine | University of Duisburg-Essen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Holger Cramer, PhD</last_name>
    <phone>+4920117425015</phone>
    <email>h.cramer@kem-med.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Heidemarie Haller, PhD</last_name>
    <phone>+4920117425044</phone>
    <email>h.haller@kem-med.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Robert-Bosch-Krankenhaus, Abteilung für Hämatologie, Onkologie und Palliativmedizin</name>
      <address>
        <city>Stuttgart</city>
        <zip>70376</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Walter E. Aulitzky, Prof. MD</last_name>
      <email>walter.aulitzky@rbk.de</email>
    </contact>
    <contact_backup>
      <last_name>Maria M. Winkler</last_name>
      <email>marcela.winkler@rbk.de</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>November 7, 2018</study_first_submitted>
  <study_first_submitted_qc>November 7, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 8, 2018</study_first_posted>
  <last_update_submitted>February 24, 2020</last_update_submitted>
  <last_update_submitted_qc>February 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universität Duisburg-Essen</investigator_affiliation>
    <investigator_full_name>Holger Cramer</investigator_full_name>
    <investigator_title>Research Director</investigator_title>
  </responsible_party>
  <keyword>Hematologic Neoplasms</keyword>
  <keyword>Supportive Therapy</keyword>
  <keyword>Fatigue</keyword>
  <keyword>Mind-body medicine</keyword>
  <keyword>Complementary and alternative medicine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hematologic Neoplasms</mesh_term>
    <mesh_term>Hematologic Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Upon reasonable request.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

